Trial Profile
The effect of ipragliflozin on ectopic fat accumulation in non-obese type 2 diabetic patients with increased visceral fat
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Aug 2017
Price :
$35
*
At a glance
- Drugs Ipragliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Astellas Pharma
- 01 Aug 2017 Results assessing effect of ipragliflozin on ectopic fat accumulation in non-obese type 2 diabetic patients with increased visceral fat were published in the Diabetes Therapy.
- 04 Feb 2017 Status changed from recruiting to completed.
- 20 Oct 2015 New trial record